3rd Quarter - Report

HARMONY BIOSCIENCES for HARMONY BIOSCIENCES

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.

LobbyistCovered position, as disclosed
CATE MCCANLESS —
GEOFFREY WERTH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 4348 (117th), H.R. 8641 (117th), S. 670 (117th), H.R. 2623 (117th), H.R. 7667 (117th), H.R. 6963 (117th), H.R. 6833 (117th), H.R. 5585 (117th), H.R. 1730 (117th), H.R. 5376 (117th), H.R. 6000 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.